Familial and acquired long QT syndrome and the cardiac rapid delayed rectifier potassium current

Clinical and Experimental Pharmacology and Physiology

Volumn 27, Issue 10, 2000, Pages 753-766

  Witchel, Harry J ^a   Hancox, Jules C ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

Author keywords

Cardiac arrhythmia; HERG; Human ether a go go related gene; I(Kr); Long QT syndrome; LQTS; Potassium channel; Rapidly activating delayed rectifier K+ current

Indexed keywords

ALMOKALANT; AMIODARONE; ANTIARRHYTHMIC AGENT; ANTIHISTAMINIC AGENT; ANTIINFECTIVE AGENT; ASTEMIZOLE; AZIMILIDE; BEPRIDIL; BRETYLIUM; CHLORPROMAZINE; DISOPYRAMIDE; DOFETILIDE; ERYTHROMYCIN; HALOPERIDOL; IBUTILIDE; NEUROLEPTIC AGENT; PENTAMIDINE; PRENYLAMINE; PROCAINAMIDE; PROPAFENONE; QUINIDINE; QUININE; SEMATILIDE; SERTINDOLE; SOTALOL; TEDISAMIL; TERFENADINE; TERODILINE; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG;

ANTIARRHYTHMIC ACTIVITY; CLINICAL FEATURE; CLINICAL TRIAL; FAMILIAL DISEASE; HEART ARRHYTHMIA; HEART MUSCLE POTENTIAL; HEART REPOLARIZATION; HUMAN; LONG QT SYNDROME; NONHUMAN; POTASSIUM CURRENT; REVIEW; SUDDEN DEATH; TORSADE DES POINTES;

ACTION POTENTIALS; ANTI-ARRHYTHMIA AGENTS; ARRHYTHMIA; CALCIUM CHANNEL BLOCKERS; CATION TRANSPORT PROTEINS; DEATH, SUDDEN, CARDIAC; DELAYED RECTIFIER POTASSIUM CHANNELS; DNA-BINDING PROTEINS; ETHER-A-GO-GO POTASSIUM CHANNELS; HEART; HUMANS; LONG QT SYNDROME; POTASSIUM CHANNELS; POTASSIUM CHANNELS, VOLTAGE-GATED; TRANS-ACTIVATORS;

EID: 0033798205     PISSN: 03051870     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1681.2000.03337.x     Document Type: Review

References (160)

1. QT interval prolongation predicts cardiovascular mortality in an apparently healthy population
2. Mechanisms and control of repolarization
3. + current. Differential sensitivity to block by class III antiarrhythmic agents
4. Role of delayed rectifier potassium channels in cardiac repolarization and arrhythmias
5. The long QT syndrome: A prospective international study
6. The long QT syndrome: Prospective longitudinal study of 328 families
7. Effects of unilateral cardiac sympathetic denervation on the ventricular fibrillation threshold
8. Congenital myocardial sympathetic dysinnervation (CMSD): A structural defect of idiopathic long QT syndrome
9. Bradycardia-dependent triggered activity: Relevance to drug-induced multiform ventricular tachycardia
10. Quinidine induced action potential prolongation, early afterdepolarisations, and triggered activity in canine Purkinje fibers: Effects of stimulation rate, potassium, and magnesium
11. Ventricular tachyarrhythmias related to early after depolarisations and triggered firing: Relationship to QT interval prolongation and potential therapeutic role for calcium channel blocking agents
12. 2+ current
13. Proarrhythmia related to prolongation of repolarisation: Mechanisms, monitoring, prevention, and management
14. Overexpression of a human potassium channel suppresses cardiac hyperexcitability in rabbit ventricular myocytes
15. Positional cloning of a novel potassium channel gene: KvLQT1 mutations cause cardiac arrhythmias
16. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia
17. KvLQT1 and Isk (minK) proteins associate to form the I(Ks) cardiac potassium channel
18. Coassembly of KvLQT1 and minK (Isk) proteins to form cardiac I(Ks) potassium channel
19. MiRP1 forms I(Kr) potassium channels with HERG and is associated with cardiac arrhythmia
20. A family of potassium channel genes related to eag in Drosophila and mammals
21. A molecular basis for cardiac arrhythmia: HERG mutations cause long QT syndrome
22. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the I(Kr) potassium channel
23. Molecular studies of voltage-gated potassium channels
24. + channel in mouse and human hearts
25. Crystal structure and functional analysis of the HERG potassium channel N terminus: A eukaryotic PAS domain
26. A plethora of mechanisms in the HERG-related long QT syndrome. Genetics meets electrophysiology
27. HERG, a human inward rectifier in the voltage gated potassium channel family
28. The inward rectification mechanism of the HERG cardiac potassium channel
29. A quantitative analysis of the activation and inactivation kinetics of HERG expressed in Xenopus oocytes
30. Properties of HERG channels stably expressed in HEK 293 cells studied at physiological temperature
31. Time course and voltage dependence of expressed HERG current compared with native 'rapid' delayed rectifier K current during the cardiac ventricular action potential
32. Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II
33. + channel blockade and to increases in heart rate. Implications for gene-specific therapy
34. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium
35. Classification of antiarrhythmic actions
36. Quinidine
37. + current by dofetilide
38. Differential effects of the new class III agent dofetilide on potassium currents in guinea pig cardiomyocytes
39. Two components of delayed rectifier current in canine atrium and ventricle. Does I(Ks) play a role in the reverse rate dependence of class III agents?
40. What should we expect from the next generation of antiarrhythmic drugs?
41. Electrophysiological effects of E4031, a drug with selective class III properties, in man
42. Combined potassium and calcium channel antagonistic activities as a basis for neutral frequency dependent increase in action potential duration: Comparison between BRL-32872 and azimilide
43. Electrophysiological effect of BRL-32872, a novel antiarrhythmic agent with potassium and calcium channel blocking properties, in guinea pig cardiac isolated preparations
44. + channel. Open-channel block by methanesulfonanilides
45. High affinity open channel block by dofetilide of HERG expressed in a human cell line
46. Molecular physiology and pharmacology of HERG. Single-channel currents and block by dofetilide
47. + channels: Frequency-dependent effects of quinidine on the relationship between action potential duration and refractoriness in the canine heart in situ
48. Electrophysiologic basis for the antiarrhythmic actions of sotalol and comparison with other agents
49. Differential effects of the new class III antiarrhythmic agents almokalant, E-4031 and D-sotalol, and of quinidine, on delayed rectifier currents in guinea pig ventricular myocytes
50. Sotalol: An important new antiarrhythmic
51. Effect of D-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival with oral D-Sotalol
52. Mortality in the Survival With ORal D-sotalol (SWORD) trial: Why did patients die?
53. Torsades de pointes with administration of high-dose intravenous D-sotalol to a patient with congestive heart failure
54. Role of interventricular dispersion of repolarization in acquired torsade-de-pointes arrhythmias: Reversal by magnesium
55. Changes in atrioventricular conduction properties with refractory-period modulation
56. Clofilium in the isolated perfused rabbit heart: A new model to study proarrhythmia induced by class III antiarrhythmic drugs
57. + current in atrial tumor cells (AT-1 cells)
58. Specific block of cloned Herg channels by clofilium and its tertiary analog LY97241
59. + channels expressed in Xenopus oocytes reduces rectification by shifting the voltage dependence of inactivation
60. Azimilide dihydrochloride, a novel antiarrhythmic agent
61. Blockade of HERG channels by the class III antiarrhythmic azimilide: Mode of action
62. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone
63. Amiodarone in long term prophylaxis
64. Electrophysiologic effects of chronic amiodarone therapy and hypothyroidism, alone and in combination, on guinea pig ventricular myocytes
65. Inhibitory effects of the class III antiarrhythmic drug amiodarone on cloned HERG potassium channels
66. Oral amiodarone
67. + current, on repolarization in human and guinea pig ventricular myocytes
68. Combined potassium and calcium channel blocking activities as a basis for antiarrhythmic efficacy with low proarrhythmic risk: Experimental profile of BRL-32872
69. Regional attitudes of generalists, specialists, and subspecialists about management of atrial fibrillation
70. The value of quinidine in cases of auricular fibrillation and methods of studying the clinical reaction
71. Risks and benefits of antiarrhythmic therapy
72. Incidence and clinical features of the quinidine associated long QT syndrome: Implications for patient care
73. Modulation of HERG potassium channels by extracellular magnesium and quinidine
74. Channel specificity in antiarrhythmic drug action: Mechanism of potassium channel block and its role in suppressing and aggravating cardiac arrhythmias
75. Incidence of proarrhythmic effects from quinidine in the outpatient treatment of benign or potentially lethal ventricular arrhythmias
76. Effect of disopyramide on potassium currents in rabbit ventricular myocytes
77. Stereoselective effects of disopyramide enantiomers in humans
78. Guidelines for the use of propafenone in treating supraventricular arrhythmias
79. Propafenone preferentially blocks the rapidly activating component of delayed rectifier K current in guinea pig ventricular myocytes
80. Cellular and clinical electrophysiology of verapamil-sensitive ventricular tachycardias
81. + channels involved in long QT syndromes, are targets for calcium channel blockers
82. Mechanism of block and identification of the verapamil binding domain to HERG potassium channels
83. Lack of triggered automaticity despite repolarization abnormalities due to bepridil and lidoflazine
84. Nine cases of torsade de pointes with bepridil administration
85. 2+ channels by Ro 40-5967
86. + currents in human fusion-competent myoblasts
87. The acute effects of intravenously administered mibefradil, a new calcium antagonist, on the electrophysiologic characteristics of the human heart
88. Safety of mibefradil, a new once-a-day, selective T-type calcium channel antagonist
89. Inhibition of HERG channels stably expressed in a mammalian cell line by the antianginal agent perhexiline maleate
90. Concentration dependent cardiotoxicity of terodiline in patients treated for urinary incontinence
91. + current by therapeutic concentrations of the antispasmodic agent terodiline
92. Basic mechanisms underlying prenylamine-induced 'torsade de pointes': Differences between prenylamine and fendiline due to basic actions of the isomers
93. The effects of prenylamine on single ventricular myocytes of guinea-pig
94. Torsades de pointes occurring in association with terfenadine use
95. Torsades de pointes after treatment with terfenadine and ketoconazole
96. Mechanism of the cardiotoxic actions of terfenadine
97. Blockade of multiple human cardiac potassium currents by the antihistamine terfenadine: Possible mechanism for terfenadine associated cardiotoxicity
98. HERG, a primary human ventricular target of the non-sedating antihistamine terfenadine
99. Blockade of HERG channels expressed in Xenopus oocytes by the histamine receptor antagonists terfenadine and astemizole
100. + channel family by ebastine
101. 1 receptor blocker cetirizine compared with other second-generation antihistamines
102. Life threatening ventricular arrhythmia (torsade de pointes) after haloperidol overdose
103. The inhibitory effect of the antipsychotic drug haloperidol on HERG potassium channels expressed in Xenopus oocytes
104. The antipsychotic agent sertindole is a high affinity antagonist of the human cardiac potassium channel HERG
105. Effect of imipramine on calcium and potassium currents in isolated bovine ventricular myocytes
106. Further characterization of the effects of imipramine on plateau membrane currents in guinea-pig ventricular myocytes
107. Inhibition of the current of heterologously expressed HERG potassium channels by imipramine and amitriptyline
108. Blockade of HERG, and Kv1.5 by ketoconazole
109. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes
110. QT interval prolongation by non-cardiovascular drugs: Issues and solutions for novel drug development
111. Long QT syndrome-associated mutations in the per-arnt-Sim (PAS) domain of HERG potassium channels accelerate channel deactivation
112. The human Delta1261 mutation of the HERG potassium channel results in a truncated protein that contains a subunit interaction domain and decreases the channel expression
113. +-channel dysfunction in an inherited cardiac arrhythmia
114. Four novel KvLQT1 and four novel HERG mutations in familial long-QT syndrome
115. Voltage-shift of the current activation in HERG S4 mutation (R534C) in LQT2
116. Novel KCNQ1 and HERG missense mutations in Dutch long-QT families
117. A mutation in HERG associated with notched T waves in long QT syndrome
118. Missense mutation in the pore region of HERG causes familial long QT syndrome
119. Novel missense mutation (G601S) of HERG in a Japanese long QT syndrome family
120. Multiple different missense mutations in the pore region of HERG in patients with long QT syndrome
121. Novel missense mutation in the cyclic nucleotide-binding domain of HERG causes long QT syndrome
122. + channel splice variant common in human heart lacks a C-terminal domain required for expression of rapidly activating delayed rectifier current
123. C-terminal HERG mutations: The role of hypokalemia and a KCNQ1-associated mutation in cardiac event occurrence
124. QT prolongation and the antiarrhythmic efficacy of amiodarone
125. Influence of dofetilide on QT-interval duration and dispersion at various heart rates during exercise in humans
126. + currents in heart cells
127. Proarrhythmic effects of the class III agent almokalant: Importance of infusion rate, QT dispersion, and early afterdepolarisations
128. + current by almokalant in rabbit ventricular myocytes
129. Antiarrhythmic effects of selective prolongation of refractoriness. Electrophysiologic actions of sematilide HCl in humans. Circulation
130. + channel, I(Kr), and effects on myocardial refractoriness for class III antiarrhythmic agents
131. Electrophysiology and pharmacology of ibutilide
132. + current (I(Kr)) in AT-1 cells. Concentration-, time-, voltage-, and use-dependent effects
133. Effects of tedisamil, atenolol and their combination on heart- and rate-dependent QT interval in healthy volunteers
134. + currents in mammalian cardiac and glial cells
135. Protection against programmed electrical stimulation-induced ventricular tachycardia and sudden cardiac death by NE-10064, a class III antiarrhythmic drug
136. Precordial QT interval dispersion as a marker of torsade de pointes. Disparate effects of class Ia antiarrhythmic drugs and amiodarone
137. Inhibition of cardiac potassium currents by the vesnarinone analog OPC-18790: Comparison with quinidine and dofetilide
138. Propafenone
139. Potassium channel blocking properties of propafenone in rabbit atrial myocytes
140. In vivo and in vitro antiarrhythmic and arrhythmogenic effects of N-acetyl procainamide
141. Torsade de pointes ventricular tachycardia: A complication of disopyramide shared with quinidine
142. Prenylamine-induced ventricular tachycardia and syncope controlled by ventricular pacing
143. Cardiac actions of antihistamines
144. Prolongation of the corrected QT and torsades de pointes cardiac arrhythmia associated with intravenous haloperidol in the medically ill
145. Cardiotoxicity of amitriptyline
146. + current activation in guinea pig ventricular myocytes
147. Cardiovascular effects of phenothiazines
148. A survey of sudden death associated with the use of antipsychotic or antidepressant drugs: 49 Cases in Finland
149. Thioridazine lengthens repolarization of cardiac ventricular myocytes by blocking the delayed rectifier potassium current
150. Safety concerns over antipsychotic drug, sertindole
151. Erythromycin induced long QT syndrome: Concordance with quinidine and underlying cellular electrophysiologic mechanism
152. Erythromycin blocks the rapid component of the delayed rectifier potassium current and lengthens repolarization of guinea pig ventricular myocytes
153. A prospective study of the effect of IV pentamidine therapy on ventricular arrhythmias and QT(c) prolongation in HIV-infected patients
154. A comparison of the pharmacokinetic and pharmacodynamic properties of quinine and quinidine in healthy Thai males
155. The pharmacokinetics and electrocardiographic effects of chloroquine in healthy subjects
156. Cardiac effects of anti-malarial treatment with halofantrine
157. Cisapride and fatal arrhythmia
158. Inhibition of the human ether-a-go-go-related gene (HERG) potassium channel by cisapride: Affinity for open and inactivated states
159. Images in clinical medicine. Congenital long-QT syndrome
160. 2+ channel agonist Bay K 8644